The non-exclusive license covers the use of mesenchymal stem cells obtained from the patient’s bone marrow to develop regenerative therapy for spinal cord injuries and brain infarction. Experiments for stroke patients (phase III) are already done at Sapporo Medical...
Wako distributes already Incella’s Screenfect transfection reagents. The collaboration has been widened on liposome synthesis based on combinatorial chemistry, including some investment. Nikkei Biotech, April 28, 2014
According to officials at Chiba University, reliability of the study is low, scientific falue is poor, and there may be a problem of conflict of interest. Nikkei Biotech news release, April 27, 2014
The procedure, codeveloped by Nissan Chemicals and Nipro, is based on a bag system with methylcellulose and gellan as protecting agent. Kh-ES1 cells were used as a model NEDO news release, April 25, 2014
The new company, YL Biologics, Tokyo, will develop biosimilars such as Embrel (Etanercept), an anti-TNF used as antirheumatic agent. Yoshindo Pharmaceuticals news release, April 24, 2014
